Prognostic Value of Asymmetric Dimethylarginine in Patients with Heart Failure: A Systematic Review and Meta-analysis.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
12
2019
revised:
22
03
2020
accepted:
22
05
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
17
4
2021
Statut:
epublish
Résumé
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is reported to be a risk factor for cardiovascular disease. The purpose of the present study is to investigate whether ADMA is an independent predictor for future mortality and adverse clinical events among patients with heart failure (HF). Electronic literature databases (Central, MEDLINE, and Embase) were searched for relevant observational studies on the prognostic value of ADMA in HF patients published before January 2019. Pooled hazard ratios (HRs) or odds ratio and the corresponding 95% confidence interval (CI) were calculated for risk evaluation. 10 studies with 2195 participants were identified and analyzed. The pooled HR of composite clinical events for the highest vs. lowest quartiles from categorical variable results was 1.34 (95% CI: 1.15-1.57, ADMA is an independent predictor for composite clinical outcomes among HF patients with both short-term and long-term prognostic value.
Identifiants
pubmed: 32714983
doi: 10.1155/2020/6960107
pmc: PMC7355346
doi:
Substances chimiques
N,N-dimethylarginine
63CV1GEK3Y
Arginine
94ZLA3W45F
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6960107Informations de copyright
Copyright © 2020 Wenjun Pan et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interests.
Références
Mol Cell Biochem. 2010 Jan;333(1-2):191-201
pubmed: 19618122
Int Heart J. 2008 May;49(3):303-11
pubmed: 18612188
Eur Heart J. 2008 Oct;29(20):2506-13
pubmed: 18687662
Microvasc Res. 2011 Nov;82(3):391-6
pubmed: 21722652
Eur J Clin Invest. 2003 May;33(5):370-5
pubmed: 12713449
Am J Hypertens. 2002 Jul;15(7 Pt 1):590-3
pubmed: 12118904
Circulation. 2003 Jan 28;107(3):429-36
pubmed: 12551867
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):2037-42
pubmed: 17569878
Circulation. 2017 May 30;135(22):e1054-e1091
pubmed: 28446515
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Circ Res. 2015 Oct 9;117(9):793-803
pubmed: 26259881
Nutr Metab Cardiovasc Dis. 2010 Jun;20(5):341-9
pubmed: 19748251
Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1455-9
pubmed: 12805079
Eur J Heart Fail. 2008 May;10(5):463-6
pubmed: 18430606
Int J Cardiol. 2012 Nov 29;161(3):137-42
pubmed: 21856022
Atherosclerosis. 2011 Nov;219(1):304-10
pubmed: 21726864
J Card Fail. 2012 Dec;18(12):904-11
pubmed: 23207078
J Am Coll Cardiol. 2018 Aug 14;72(7):721-733
pubmed: 30092948
Transl Res. 2008 Jul;152(1):24-30
pubmed: 18593634
Healthcare (Basel). 2016 Jul 08;4(3):
pubmed: 27417628
Brain Behav Immun. 2016 Oct;57:144-150
pubmed: 27013355
Cardiovasc Res. 1998 Mar;37(3):667-75
pubmed: 9659450
Clin Pharmacol Ther. 2010 Oct;88(4):506-12
pubmed: 20827268
Int J Cardiol. 2018 Jun 15;261:109-113
pubmed: 29550017
Life Sci. 1998;62(26):2425-30
pubmed: 9651109
Physiol Genomics. 2003 Aug 15;14(3):251-60
pubmed: 12824457
Circulation. 2009 Mar 31;119(12):1592-600
pubmed: 19289633
Heart Vessels. 2003 Sep;18(4):177-82
pubmed: 14520484
Clin Chem Lab Med. 2004;42(12):1377-83
pubmed: 15576299
Pharmacol Rep. 2006;58 Suppl:16-20
pubmed: 17332667
Atherosclerosis. 2012 Dec;225(2):504-10
pubmed: 23092827
J Am Coll Cardiol. 2018 May 15;71(19):2079-2088
pubmed: 29747827
Lancet. 1992 Mar 7;339(8793):572-5
pubmed: 1347093
Eur Heart J. 2015 Aug 14;36(31):2050-2060
pubmed: 25911648
Heart Vessels. 2016 Jul;31(7):1100-8
pubmed: 26135926
Clin Cardiol. 2003 Oct;26(10):458-64
pubmed: 14579916
Transl Res. 2013 Jul;162(1):26-33
pubmed: 23499315
Heart. 2012 Jun;98(11):860-4
pubmed: 22422591